Trials / Not Yet Recruiting
Not Yet RecruitingNCT06652555
The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study
The CNS AE of Lorlatinib in Patients with ALK-positive Advanced NSCLC
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to investigate the incidence and risk factors of central nervous system adverse events of Lorlatinib in patients with ALK-positive advanced non-small cell lung cancer.
Detailed description
The goal of this study is to investigate the incidence and risk factors of central nervous system adverse events of Lorlatinib in patients with ALK-positive advanced non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Group 1 | without Intervention |
Timeline
- Start date
- 2024-10-30
- Primary completion
- 2026-09-29
- Completion
- 2027-09-29
- First posted
- 2024-10-22
- Last updated
- 2024-10-22
Source: ClinicalTrials.gov record NCT06652555. Inclusion in this directory is not an endorsement.